| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,627,000 |
| Market
Cap: |
11.63(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1459 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering, cquiring and developing therapeutics and diagnostics to treat and prevent human disease. Co.'s portfolio is primarily composed of immunology, central nervous system (CNS), and infectious disease product candidates. Co.'s key product candidate within its immunology pipeline is TNX-1500, a humanized monoclonal antibody, directed against CD40-ligand, engineered to modulate binding to Fc receptors, that is being developed as a prophylaxis against organ transplant rejection. Among the CNS candidates in development is TNX-1300 which is for the treatment of life-threatening cocaine intoxication.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
20,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$34,200 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mario Ernest |
Director |
– • – |
2015-07-17 |
4 |
B |
$7.50 |
$187,500 |
D/D |
25,000 |
225,472 |
2.39 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-07-17 |
4 |
B |
$7.50 |
$45,000 |
I/I |
6,000 |
6,000 |
2.66 |
- |
|
| Saks Samuel R |
Director |
– • – |
2015-07-17 |
4 |
B |
$7.50 |
$75,000 |
D/D |
10,000 |
32,550 |
2.39 |
- |
|
| Gershell Leland |
Chief Financial Officer |
• – – |
2015-07-17 |
4 |
B |
$7.50 |
$7,500 |
D/D |
1,000 |
18,860 |
2.74 |
- |
|
| Rhodes John B |
Director |
– • – |
2015-07-17 |
4 |
B |
$7.50 |
$45,000 |
D/D |
6,000 |
81,196 |
2.39 |
- |
|
| Daugherty Bruce |
See Remarks |
• – – |
2015-06-30 |
5 |
A |
$4.99 |
$17,625 |
D/D |
3,532 |
63,049 |
|
- |
|
| Sullivan Gregory M |
Chief Medical Officer |
• – – |
2015-06-30 |
5 |
A |
$4.99 |
$17,625 |
D/D |
3,532 |
20,457 |
|
- |
|
| Sullivan Gregory M |
Chief Medical Officer |
• – – |
2015-06-11 |
4 |
B |
$8.38 |
$37,710 |
D/D |
4,500 |
7,231 |
2.74 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-17 |
4 |
B |
$7.18 |
$7,180 |
D/D |
1,000 |
65,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-16 |
4 |
B |
$6.85 |
$6,853 |
D/D |
1,000 |
64,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-13 |
4 |
B |
$7.21 |
$7,210 |
D/D |
1,000 |
63,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-12 |
4 |
B |
$7.26 |
$7,260 |
D/D |
1,000 |
62,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-11 |
4 |
B |
$7.00 |
$7,000 |
D/D |
1,000 |
61,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-10 |
4 |
B |
$6.90 |
$6,900 |
D/D |
1,000 |
60,074 |
2.81 |
- |
|
| Mather Charles E Iv |
Director |
– • – |
2015-03-10 |
4 |
B |
$6.80 |
$6,800 |
D/D |
1,000 |
11,830 |
2.39 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-09 |
4 |
B |
$6.50 |
$6,500 |
D/D |
1,000 |
59,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-06 |
4 |
B |
$6.45 |
$6,450 |
D/D |
1,000 |
58,074 |
2.81 |
- |
|
| Mario Ernest |
Director |
– • – |
2015-03-06 |
4 |
B |
$6.57 |
$26,280 |
D/D |
4,000 |
200,472 |
2.39 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-05 |
4 |
B |
$6.48 |
$6,480 |
D/D |
1,000 |
57,074 |
2.81 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-03-04 |
4 |
B |
$6.05 |
$6,050 |
D/D |
1,000 |
56,074 |
2.81 |
- |
|
| Mario Ernest |
Director |
– • – |
2015-02-09 |
4 |
B |
$5.85 |
$175,500 |
D/D |
30,000 |
196,472 |
2.39 |
- |
|
| Gershell Leland |
Chief Financial Officer |
• – – |
2015-02-09 |
4 |
B |
$5.85 |
$29,250 |
D/D |
5,000 |
17,860 |
2.74 |
- |
|
| Lederman Seth |
Chief Executive Officer |
• • – |
2015-02-09 |
4 |
B |
$5.85 |
$29,250 |
D/D |
5,000 |
55,074 |
2.81 |
- |
|
| Mario Ernest |
Director |
– • – |
2014-12-18 |
4 |
OE |
$4.25 |
$127,500 |
D/D |
30,000 |
166,472 |
|
- |
|
| Gershell Leland |
Chief Financial Officer |
• – – |
2014-12-17 |
4 |
OE |
$4.25 |
$15,003 |
D/D |
3,530 |
12,860 |
|
- |
|
128 Records found
|
|
Page 5 of 6 |
|
|
0.01 (5.2%) 
